Safety Aspects of AAV- and Lentivirus-based Cell and Gene Therapy

10:15 AM - 11:15 AM (PDT), Thursday, June 16, 2022 ・ Upper Level, Session Room 2
During recent years, a few challenges and risks to patients have been reported emerging from viral vectors platforms that lead to integration into host genomic DNA or from high vector titers resulting in fatal toxicity side effects.
In light of these findings, we are motivated to discuss the perils and opportunities of these precision medicine modalities, with the focus on increasing safety and reducing risk by:
• Optimal vector dose
• Improving transduction protocols
• Genetic screening
• Minimizing toxic side effects to patients
Moderator
photo
Scientific Content Writer
PerkinElmer
Speakers
photo
Scientific Director Research
Takeda Oncology
photo
Professor
University of California, Los Angeles
photo
Chief Scientific Officer
Pioneering Medicines VII, Inc
photo
CEO and Founder
Sirion Biotech